Norway Medication Assisted Therapy (MAT) Market to 2032
Overview
The Norway Medication Assisted Therapy (MAT) Market is expected to reach a 132.03 by 2032 and is projected to grow at a CAGR of 11.25% from 2025 to 2032.
Revenue, 2024 ()
75.50
Forecast, 2032 ()
132.03
CAGR, 2024 - 2032
11.25%
Report Coverage
Norway
Norway Medication Assisted Therapy (MAT) Market 2018-2032
Norway Medication Assisted Therapy (MAT) Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 75.50
- Projected Market Size (2032): 132.03
- CAGR (2025-2032): 11.25%
Key Findings of Norway Medication Assisted Therapy (MAT) Market
- The Norway Medication Assisted Therapy (MAT) Market was valued at 75.50 in 2024.
- The Norway Medication Assisted Therapy (MAT) Market is likely to grow at a CAGR of 11.25% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Adults in Population Type Segment accounted for the largest share of the market with a revenue of 72.09
- The fastest growing segment Buprenorphine and Naloxone in Products Segment grew Fastest with a CAGR of 13.71% during the forecast period from 2024 to 2032.
Norway Medication Assisted Therapy (MAT) Market Scope
Norway Medication Assisted Therapy (MAT) Market Segmentation & Scope
Type
- Therapy
- Medication
Products
- Acamprosate
- Disulfarm
- Naloxone
- Metadone
- Buprenorphine
- Naltrexone
- Buprenorphine and Naloxone
Drug Type
- Branded
- Generics
End User
- Others
- Homecare
- Speciality Centers
- Hospitals
- Rehabilitation Clinics
Distribution Channel
- Others
- Online Pharmacy
- Retail Pharmacy
- Direct Tender
- Hospital Pharmacy
Population Type
- Teenage
- Adults
Dosage Form
- Extented Release
- Immediate Release
Route of Administration
- Others
- Parenteral
- Oral
Norway Medication Assisted Therapy (MAT) Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2020 |
| Unit | Revenue in |
| Market Value in 2024 | 75.50 |
| Market Value in 2032 | 132.03 |
| CAGR (2025-2032) | 11.25% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Type,Products,Drug Type,End User,Distribution Channel,Population Type,Dosage Form,Route of Administration |
Regional Insights:
-
Leading Market (2024-2032): Norway, leading in terms of revenue 75.50 in 2024
- Key Country: Norway, leading in terms of revenue with value of 75.50 in 2024.
Segments and Scope
-
Norway Medication Assisted Therapy (MAT) Market to 2032, By Type
- Medication is the largest segment in Norway Medication Assisted Therapy (MAT) Market to 2032 with a revenue of 42.14 in the year 2024.
- Medication is the Fastest growing segment in Norway Medication Assisted Therapy (MAT) Market to 2032 with a Growth rate of 11.94 % in forecast period 2025-2032.
-
Norway Medication Assisted Therapy (MAT) Market to 2032, By Products
- Buprenorphine and Naloxone is the largest segment in Norway Medication Assisted Therapy (MAT) Market to 2032 with a revenue of 10.66 in the year 2024.
- Buprenorphine and Naloxone is the Fastest growing segment in Norway Medication Assisted Therapy (MAT) Market to 2032 with a Growth rate of 13.71 % in forecast period 2025-2032.
-
Norway Medication Assisted Therapy (MAT) Market to 2032, By Drug Type
- Generics is the largest segment in Norway Medication Assisted Therapy (MAT) Market to 2032 with a revenue of 37.25 in the year 2024.
- Generics is the Fastest growing segment in Norway Medication Assisted Therapy (MAT) Market to 2032 with a Growth rate of 12.17 % in forecast period 2025-2032.
-
Norway Medication Assisted Therapy (MAT) Market to 2032, By End User
- Rehabilitation Clinics is the largest segment in Norway Medication Assisted Therapy (MAT) Market to 2032 with a revenue of 31.09 in the year 2024.
- Rehabilitation Clinics is the Fastest growing segment in Norway Medication Assisted Therapy (MAT) Market to 2032 with a Growth rate of 12.54 % in forecast period 2025-2032.
-
Norway Medication Assisted Therapy (MAT) Market to 2032, By Distribution Channel
- Hospital Pharmacy is the largest segment in Norway Medication Assisted Therapy (MAT) Market to 2032 with a revenue of 22.06 in the year 2024.
- Hospital Pharmacy is the Fastest growing segment in Norway Medication Assisted Therapy (MAT) Market to 2032 with a Growth rate of 12.85 % in forecast period 2025-2032.
-
Norway Medication Assisted Therapy (MAT) Market to 2032, By Population Type
- Adults is the largest segment in Norway Medication Assisted Therapy (MAT) Market to 2032 with a revenue of 72.09 in the year 2024.
- Adults is the Fastest growing segment in Norway Medication Assisted Therapy (MAT) Market to 2032 with a Growth rate of 11.33 % in forecast period 2025-2032.
-
Norway Medication Assisted Therapy (MAT) Market to 2032, By Dosage Form
- Immediate Release is the largest segment in Norway Medication Assisted Therapy (MAT) Market to 2032 with a revenue of 26.19 in the year 2024.
- Immediate Release is the Fastest growing segment in Norway Medication Assisted Therapy (MAT) Market to 2032 with a Growth rate of 12.48 % in forecast period 2025-2032.
-
Norway Medication Assisted Therapy (MAT) Market to 2032, By Route of Administration
- Oral is the largest segment in Norway Medication Assisted Therapy (MAT) Market to 2032 with a revenue of 23.08 in the year 2024.
- Oral is the Fastest growing segment in Norway Medication Assisted Therapy (MAT) Market to 2032 with a Growth rate of 12.76 % in forecast period 2025-2032.
Norway Medication Assisted Therapy (MAT) Market Company Share Analysis
| Company Name |
|
||
| Viatris Inc. | |||
| Indivior PLC | |||
| Mallinckrodt | |||
| Sun Pharmaceutical Industries Ltd. | |||
| Teva Pharmaceutical Industries Ltd. | |||
Norway Medication Assisted Therapy (MAT) Market Geographical Sales Distribution, 2018-2032
Norway Medication Assisted Therapy (MAT) Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The Norway Medication Assisted Therapy (MAT) Market is segmented based on Segmentation Type,Products,Drug Type,End User,Distribution Channel,Population Type,Dosage Form,Route of Administration.
Norway Medication Assisted Therapy (MAT) Market was valued at USD 75.50(Revenue in ) in 2020.
Norway Medication Assisted Therapy (MAT) Market is projected to grow at a CAGR of 11.25% during the forecast period of 2024 to 2032.
The Adults segment is expected to dominate the Norway Medication Assisted Therapy (MAT) Market, holding a largest market share of 72.09 in 2024
Coming Soon....
Norway Medication Assisted Therapy (MAT) Market Scope
Norway Medication Assisted Therapy (MAT) Market Segmentation & Scope
Type
- Therapy
- Medication
Products
- Acamprosate
- Disulfarm
- Naloxone
- Metadone
- Buprenorphine
- Naltrexone
- Buprenorphine and Naloxone
Drug Type
- Branded
- Generics
End User
- Others
- Homecare
- Speciality Centers
- Hospitals
- Rehabilitation Clinics
Distribution Channel
- Others
- Online Pharmacy
- Retail Pharmacy
- Direct Tender
- Hospital Pharmacy
Population Type
- Teenage
- Adults
Dosage Form
- Extented Release
- Immediate Release
Route of Administration
- Others
- Parenteral
- Oral
Frequently Asked Questions
The Norway Medication Assisted Therapy (MAT) Market is segmented based on Segmentation Type,Products,Drug Type,End User,Distribution Channel,Population Type,Dosage Form,Route of Administration.
Norway Medication Assisted Therapy (MAT) Market was valued at USD 75.50(Revenue in ) in 2020.
Norway Medication Assisted Therapy (MAT) Market is projected to grow at a CAGR of 11.25% during the forecast period of 2024 to 2032.
The estimated market value of the Norway Medication Assisted Therapy (MAT) Market for final year is USD 132.03 ().
Norway Medication Assisted Therapy (MAT) Market Company Profiling
Frequently Asked Questions
The Norway Medication Assisted Therapy (MAT) Market is segmented based on Segmentation Type,Products,Drug Type,End User,Distribution Channel,Population Type,Dosage Form,Route of Administration.
Norway Medication Assisted Therapy (MAT) Market was valued at USD 75.50(Revenue in ) in 2020.
Norway Medication Assisted Therapy (MAT) Market is projected to grow at a CAGR of 11.25% during the forecast period of 2024 to 2032.
The estimated market value of the Norway Medication Assisted Therapy (MAT) Market for final year is USD 132.03 ().
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.